Washington, D.C. 20549
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934 (Amendment No. 1)
Filed by the Registrant: ☒
Filed by a Party other than the Registrant: ☐

Check the appropriate box:

Preliminary Proxy Statement
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
Definitive Proxy Statement
Definitive Additional Materials
Soliciting Material Pursuant to §240.14a-12
CTI BioPharma Corp.
(Name of Registrant as Specified In Its Charter)
Payment of filing fee (Check the appropriate box):
No fee required.
Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
Title of each class of securities to which transaction applies:
Aggregate number of securities to which transaction applies:
Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):
Proposed maximum aggregate value of transaction:
Total fee paid:
Fee paid previously with preliminary materials.
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
Amount Previously Paid:
Form, Schedule or Registration Statement No.:
Filing Party:
Date Filed:


This Amendment No. 1 amends and restates in its entirety the Definitive Additional Materials of CTI BioPharma Corp. (the “Company”) that were originally filed with the Securities and Exchange Commission on April 4, 2019. The original Definitive Additional Materials inadvertently omitted the Notice of Internet Availability of Proxy Materials. The purpose of this Amendment No. 1 is to include the Notice of Internet Availability of Proxy Materials in the Definitive Additional Materials.